LEXX Lexaria Bioscience Corp: Enterprise Value to EBITDA Ratio
The EV/EBITDA price chart for Lexaria Bioscience (LEXX) is currently at 0.00. Business profitability relies on payments for the use of the DehydraTECH system, which improves the absorption of oral medications. The company's developments reduce chemical waste by optimizing drug dosages. The legal purity of patents in North America ensures operational stability and minimal geopolitical risks.
Comprehensive metric breakdowns and analytics for lexariabioscience.com (LEXX)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Lexaria Bioscience|LEXX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lexaria Bioscience Corp.|LEXX - Company Debts|Debts to Book Capitalization Lexaria Bioscience Corp.|LEXX - Long-Term Debt|Company Current Liabilities Lexaria Bioscience|Quick Ratio lexariabioscience.com
- financial results and valuation multiples details:
LEXX - Net Profit|Expected Profit Lexaria Bioscience|LEXX - Company Value to Net Income|Forward P/E Multiple Lexaria Bioscience Corp.|LEXX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Lexaria Bioscience Corp.|LEXX - Operating profit EBITDA|Net earnings per share for the last 12 months Lexaria Bioscience|LEXX - Earnings per share for the trailing year|Quarterly EPS earnings growth lexariabioscience.com|LEXX - Earnings per share growth in current year|Earnings growth forecast for next year Lexaria Bioscience
Summary company analytics:Lexaria LEXX
For Lexaria Bioscience (LEXX), whose valuation depends on the trial results of its drug absorption platform, the EV/EBITDA multiple adjusted for net debt serves as an indicator of the business's real value relative to its operational efficiency. The ratio of Enterprise Value to earnings before interest, taxes, depreciation, and amortization allows an investor to assess the payback period of assets, taking into account the debt load and the potential for future licensing revenues.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MannKind Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Amphastar - EV/EBITDA Multiple|Company Value to EBITDA Pacira Corp|SPRY (ARS Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation TBPH|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple scPharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|TNXP (Tonix Pharmaceuticals Holding) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Eupraxia Pharmaceuticals, Inc. (EPRX)|BioHarvest Sciences Inc. - EV/EBITDA Multiple|EXOZ - EV/EBITDA Multiple|ORMP (oramed.com) - Enterprise Value to EBITDA Ratio|Entera Bio - Business Value to Operating Income Before Depreciation|HYFT (MindWalk Holdings) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC|EV/EBITDA Multiple CPIX|Total Company Value to Operating Income Before Depreciation Ratio Quantum BioPharma Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|Telomir Pharmaceuticals Corp (TELO) - Company Value to EBITDA|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Synergy CHC Corp SNYR|RLYB: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix Inc|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|Aptorum (APM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LYRA|IBO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|YCBD: Enterprise Value to Operating Income Before Depreciation|PainReform Limited - EV/EBITDA Multiple|Altamira Therapeutics (CYTO) - Enterprise Value to EBITDA Ratio|LIPO: EV/EBITDA Multiple|Company Value to EBITDA optinose.com (OPTN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PROC|EV/EBITDA Multiple PTPI|QLI - Company Value to EBITDA|Acelyrin, Inc. - Enterprise Value to EBITDA Ratio|TFFP: Enterprise Value to Operating Income Before Depreciation
